Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 129

1.

[Impact of treatment with acetylcholinesterase inhibitors, valproic acid and antipsychotics on aggressive behaviour in Alzheimer's type dementia].

Bidzan L, Grabowski J, Dutczak B, Bidzan M.

Psychiatr Pol. 2012 May-Jun;46(3):361-72. Polish.

PMID:
23045890
3.

Aggressive and impulsive behavior in Alzheimer's disease and progression of dementia.

Bidzan L, Bidzan M, Pąchalska M.

Med Sci Monit. 2012 Mar;18(3):CR182-9.

4.

Effects of donepezil, galantamine and rivastigmine in 938 Italian patients with Alzheimer's disease: a prospective, observational study.

Santoro A, Siviero P, Minicuci N, Bellavista E, Mishto M, Olivieri F, Marchegiani F, Chiamenti AM, Benussi L, Ghidoni R, Nacmias B, Bagnoli S, Ginestroni A, Scarpino O, Feraco E, Gianni W, Cruciani G, Paganelli R, Di Iorio A, Scognamiglio M, Grimaldi LM, Gabelli C, Sorbi S, Binetti G, Crepaldi G, Franceschi C.

CNS Drugs. 2010 Feb;24(2):163-76. doi: 10.2165/11310960-000000000-00000.

PMID:
20088621
5.
6.

Behavioral and psychological symptoms and the progression of dementia of the Alzheimer type in nursing home residents.

Bidzan L, Pachalska M, Grochmal-Bach B, Bidzan M, Jastrzebowska G.

Med Sci Monit. 2008 Nov;14(11):CR559-67.

PMID:
18971872
7.

Risk of antipsychotic drug use in patients with Alzheimer's disease treated with rivastigmine.

Suh DC, Arcona S, Thomas SK, Powers C, Rabinowicz AL, Shin H, Mirski D.

Drugs Aging. 2004;21(6):395-403.

PMID:
15084141
8.

Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease.

Morris JC, Cyrus PA, Orazem J, Mas J, Bieber F, Ruzicka BB, Gulanski B.

Neurology. 1998 May;50(5):1222-30.

PMID:
9595967
10.
11.
12.

A naturalistic study of galantamine for Alzheimer's disease.

Brodaty H, Woodward M, Boundy K, Barnes N, Allen G; NATURE Investigators.

CNS Drugs. 2006;20(11):935-43.

PMID:
17044730
13.

A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia.

Brodaty H, Ames D, Snowdon J, Woodward M, Kirwan J, Clarnette R, Lee E, Lyons B, Grossman F.

J Clin Psychiatry. 2003 Feb;64(2):134-43.

PMID:
12633121
14.

Galantamine provides sustained benefits in patients with 'advanced moderate' Alzheimer's disease for at least 12 months.

Blesa R, Davidson M, Kurz A, Reichman W, van Baelen B, Schwalen S.

Dement Geriatr Cogn Disord. 2003;15(2):79-87.

PMID:
12566596
15.

Carotid intima-media thickness as a predictor of response to cholinesterase inhibitors in Alzheimer's disease: an open-label trial.

Modrego PJ, Rios C, Pérez Trullen JM, García-Gómara MJ, Errea JM.

CNS Drugs. 2009;23(3):253-60. doi: 10.2165/00023210-200923030-00006.

PMID:
19320533
16.
17.

Olanzapine does not enhance cognition in non-agitated and non-psychotic patients with mild to moderate Alzheimer's dementia.

Kennedy J, Deberdt W, Siegal A, Micca J, Degenhardt E, Ahl J, Meyers A, Kaiser C, Baker RW.

Int J Geriatr Psychiatry. 2005 Nov;20(11):1020-7.

PMID:
16250069
18.
19.

Optimal dosing of galantamine in patients with mild or moderate Alzheimer's disease: post Hoc analysis of a randomized, double-blind, placebo-controlled trial.

Aronson S, Van Baelen B, Kavanagh S, Schwalen S.

Drugs Aging. 2009;26(3):231-9. doi: 10.2165/00002512-200926030-00004.

PMID:
19358618
20.

Domain-specific improvement of cognition on memantine in patients with Alzheimer's disease treated with rivastigmine.

Riepe MW, Adler G, Ibach B, Weinkauf B, Tracik F, Gunay I.

Dement Geriatr Cogn Disord. 2007;23(5):301-6. Epub 2007 Mar 13.

PMID:
17356273
Items per page

Supplemental Content

Write to the Help Desk